SCHEMBL23260568

SCHEMBL23260568

CCc1cc(Nc2ncc(OC)c(Nc3ccc(C4CC4)cc3P(C)(C)=O)n2)c(OC)cc1N1CCC(N2CCN(C)CC2)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 12/20 0.64
▸ ALK Q9UM73 9/20 0.64
▸ INSR P06213 8/20 0.64
▸ IGF1R P08069 8/20 0.64
▸ CHEK1 O14757 1/20 0.57
▸ AURKA O14965 1/20 0.57
▸ NUAK1 O60285 1/20 0.57
▸ JAK2 O60674 1/20 0.57
▸ STK10 O94804 1/20 0.57
▸ PRKD3 O94806 1/20 0.57
▸ SLC34A2 O95436 1/20 0.57
▸ CHEK2 O96017 1/20 0.57
▸ ABL1 P00519 1/20 0.57
▸ CD74 P04233 1/20 0.57
▸ ERBB2 P04626 1/20 0.57
▸ LCK P06239 1/20 0.57
▸ FYN P06241 1/20 0.57
▸ FES P07332 1/20 0.57
▸ CSF1R P07333 1/20 0.57
▸ YES1 P07947 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23259839 0.94 EGFR (0.74) EGFRALKINSRIGF1R
SCHEMBL23259935 0.91 INSR (0.68) EGFRALKINSRIGF1RCHEK1
SCHEMBL26095652 0.90 ALK (0.65) EGFRALKINSRIGF1RCHEK1
SCHEMBL23260566 0.90 EGFR (0.70) EGFRALKINSRIGF1R
SCHEMBL23260569 0.88 EGFR (0.58) EGFRALKINSRIGF1R
SCHEMBL30389804 0.87 EGFR (0.65) EGFRALKINSRIGF1RCHEK1
SCHEMBL23259937 0.87 EGFR (0.65) EGFRALKINSRIGF1RCHEK1
SCHEMBL24754955 0.87 EGFR (0.70) EGFRALKINSRIGF1R
SCHEMBL23260553 0.85 EGFR (0.73) EGFRALKINSRIGF1RCHEK1
SCHEMBL24179083 0.85 EGFR (0.77) EGFRALKINSRIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230133169-A1 EGFR INHIBITOR, COMPOSITION, AND METHOD FOR PREPARATION THEREOF BETTA PHARMACEUTICALS CO., LTD (CN) 2023-05-04 — — US disclosed
US-20230133169-A1 EGFR INHIBITOR, COMPOSITION, AND METHOD FOR PREPARATION THEREOF BETTA PHARMACEUTICALS CO., LTD (CN) 2023-05-04 — — US disclosed
WO-2021073498-A1 EGFR INHIBITOR, COMPOSITION, AND METHOD FOR PREPARATION THEREOF 贝达药业股份有限公司 2021-04-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230133169-A1 EGFR INHIBITOR, COMPOSITION, AND METHOD FOR PREPARATION THEREOF EGFR, ERBB2, ERBB3 EGFR 1/4885ALK 110/4885INSR 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback